Last reviewed · How we verify
Daily dosing
This drug prevents HIV infection by blocking the virus's entry into host cells.
This drug prevents HIV infection by blocking the virus's entry into host cells. Used for Prevention of HIV infection in individuals at high risk.
At a glance
| Generic name | Daily dosing |
|---|---|
| Also known as | Daily, TDF/FTC |
| Sponsor | HIV Prevention Trials Network |
| Drug class | Entry inhibitor |
| Target | HIV envelope glycoprotein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
It does this by binding to the HIV envelope glycoprotein, preventing the virus from fusing with the host cell membrane. This mechanism is effective against a wide range of HIV strains.
Approved indications
- Prevention of HIV infection in individuals at high risk
Common side effects
- Gastrointestinal adverse events
- Headache
- Fatigue
Key clinical trials
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors (PHASE1, PHASE2)
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (PHASE3)
- Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures (PHASE4)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daily dosing CI brief — competitive landscape report
- Daily dosing updates RSS · CI watch RSS
- HIV Prevention Trials Network portfolio CI